K2 HealthVentures

Excited to partner with the Phil team!

Today we announced a $60 million growth debt financing for Phil, Inc., a software-powered therapy deployment platform transforming how pharmaceutical manufacturers tackle access, affordability, and distribution. This funding will fuel Phil’s expansion and fast-track the integration of AI across its platform—helping bring therapies to patients faster and more efficiently across a wide range of conditions. http://bit.ly/45UR6fV

We are excited to partner with new portfolio company Neumora Therapeutics on a $125M financing to support their efforts to confront the global brain disease crisis. $20M is funded immediately with an additional $20 million available to be drawn at Neumora’s option; the remaining $85 million will be available for upon the achievement of certain milestones. We look forward to working with Neumora to advance the next-generation of innovative therapies for brain disease.

#ICYMI - Check out CEO & Founding Managing Director, Parag Shah's interview with Jon Chee from the Biotech Startups Podcast to learn more about creating innovative financing solutions for emerging biotech companies who have very specific needs.

"Think what your real intentions are, and then don't be scared to put them out there. And then, you know, as a good friend of mine told me in grad school, ‘really touch base with what your intentions are.’ The universe will ultimately conspire to help you, but you have to be clear about what it is." In Part 2 of The Biotech Startups Podcast our CEO & Founding Managing Director, Parag Shah and Jon Chee explore the power of clarity in intentions and how it can shape one's career trajectory. Learn how this philosophy contributed to the formation of K2HV and its dual commitment of "profit with a purpose."

Interested in learning more about how K2 HealthVentures creates innovative financing solutions for emerging biotech companies? Check out CEO & Founding Managing Director, Parag Shah's interview with Jon Chee from the Biotech Startups Podcast to discover how debt financing works and hear about Parag's career at the intersection of science, finance, and entrepreneurship.

Congrats to Umoja Biopharma on their $100 Million Series C. This financing will help advance their pipeline of in vivo CAR T cell generating therapies, which have the potential to increase effectiveness, reduce barriers, and expand access to CAR T cell therapies.

Chronic kidney disease places a significant burden on the U.S. healthcare system and, more importantly, the lives of patients. We are proud to support Evergreen Nephrology, a leader in value-based kidney care, alongside Rubicon Founders, Oak HC/FT, and other investors. This funding will fuel the company's growth by enabling its expansion into new regions and broadening the tools and resources they make available for their physician partners to improve clinical outcomes and streamline patient-centered care delivery.